How to Write a Pharmaceutical Marketing Plan: Structure and Example
A practical structure for a pharmaceutical marketing plan: situation, objectives, barriers, segments, positioning, tactics, budget, and measurement.
The short answer
A pharmaceutical marketing plan sets out where a brand is today, what it must achieve, who it needs to reach, what it will say, which tactics it will use, what it will spend, and how success will be measured. A good one fits on a few pages, ties every tactic to a specific barrier in the patient or HCP journey, and states the assumptions that would change the plan if they turn out wrong.
Every pharma brand has a plan. Many are hard to use: 80 slides of market data, a list of tactics, and a budget table that do not connect. The point of a marketing plan is to make choices and show why. This guide gives a structure that does that and a short example.
The structure
| Section | Question it answers |
|---|---|
| 1. Situation analysis | Where is the brand today, and why? |
| 2. Objectives | What must change, by how much, by when? |
| 3. Barriers | What is stopping that change? |
| 4. Target segments | Which HCPs and patients matter most? |
| 5. Positioning and messages | Why should they choose this product, for which patients? |
| 6. Strategic imperatives | The three or four things the brand must get right |
| 7. Tactics | What will be done, for whom, to remove which barrier |
| 8. Budget | What it costs and how money is split |
| 9. Measurement | How the brand will know it worked |
| 10. Risks and assumptions | What could make this plan wrong |
1. Situation analysis
Keep it focused on facts that drive decisions: market size and growth, share and trend, competitor moves, access and coverage, and the patient journey. A useful test: if a chart does not change any later section, move it to the appendix.
2. Objectives
Write objectives in numbers with a date. "Grow new-to-brand prescriptions among target rheumatologists by a defined percentage by Q4" is usable. "Increase awareness" is not, unless you say among whom, measured how, and to what level.
3. Barriers
This is the section most plans skip. Find the main reason the objective is not happening on its own. Common barriers: HCPs do not know which patients fit, prior authorization is hard, patients drop off before the first fill, or a competitor owns the first-line position. Each tactic later should point to a barrier.
4. Target segments
Define HCP and patient segments clearly enough that a media partner could build the list. See pharmaceutical market segmentation and patient segmentation.
5. Positioning and messages
State the positioning in one sentence: for which patients, against what alternative, on which benefit, with what proof. The article on drug market positioning covers how brands choose.
6 and 7. Imperatives and tactics
Imperatives are the few things that must go right. Tactics serve them. A simple table keeps this honest:
| Barrier | Imperative | Tactic | Audience | KPI |
|---|---|---|---|---|
| HCPs unsure which patients qualify | Make patient selection simple | Patient-type email series, point-of-care messaging | Target rheumatologists | Engaged target HCPs, new patient starts |
| Access delays | Ease prior authorization | Access support content, field reimbursement | Practice staff | Time to first fill |
Pharmaceutical marketing tactics matched to objectives lists common tactics by job.
8. Budget
Show spend by imperative, not just by channel. That makes it obvious if most money goes to something the plan calls secondary. Hold back a learning budget for tests. See how much to reserve for learning.
9. Measurement
Name the measure for each objective, the data source, and the comparison. "Rx lift among exposed HCPs versus a matched control, from a claims-based attribution study" is a measurement plan. The pharma programmatic measurement framework shows how media connects to Rx outcomes.
10. Risks and assumptions
List the assumptions the plan depends on, such as "coverage reaches parity by mid-year." For each, note what you will do if it fails. This section turns a static plan into one you can manage.
A short example
Hypothetical example. A second-to-market oral therapy in a chronic condition has 8% share of new patients. The objective is 12% by year end.
- Main barrier: HCPs default to the first brand they learned, and many do not know the new brand's dosing advantage.
- Positioning: for patients who struggle with the incumbent's dosing schedule.
- Imperatives: make the dosing benefit known to high-volume HCPs; make switching easy; support persistence.
- Tactics: NPI-matched programmatic and endemic reach to top tiers; email and field on switching; DTC aimed at patients unhappy with current dosing; adherence support.
- Measurement: new-to-brand share by tier, with a holdout of low-priority HCPs for media incrementality.
Common mistakes
- Long situation analysis, short strategy.
- Tactics carried over from last year with no barrier attached.
- Objectives that cannot be measured with available data.
- No stated assumptions, so nobody knows when to change course.
Practical takeaway
Take your current plan and fill in the barrier-imperative-tactic-KPI table. Any tactic you cannot link to a barrier is a candidate to cut or test, and any barrier with no tactic is a gap.
Frequently asked questions
What are the parts of a pharmaceutical marketing plan?
Situation analysis, objectives, target segments, positioning and messages, strategic imperatives, tactics by audience, budget, measurement plan, and risks with the assumptions behind them.
How long should a pharma brand plan be?
The core plan should be short enough for leadership to read in one sitting, often under ten pages, with detailed tactical plans and data in appendices.
How often is a pharma marketing plan updated?
Most brands write an annual plan and review it quarterly. Launch brands often revisit it more often in the first year.
Sources
- FDA, Prescription Drug Advertising
- FDA, Office of Prescription Drug Promotion (OPDP)
- CMS, Open Payments
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.